Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor

Genetic instability of cancer cells generates resistance after initial responses to chemotherapeutic agents. Several oncolytic viruses have been designed to exploit specific signatures of cancer cells, such as important surface markers or pivotal signaling pathways for selective replication. It is l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer gene therapy 2010-04, Vol.17 (4), p.244-255
Hauptverfasser: Tseng, J-C, Granot, T, DiGiacomo, V, Levin, B, Meruelo, D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 255
container_issue 4
container_start_page 244
container_title Cancer gene therapy
container_volume 17
creator Tseng, J-C
Granot, T
DiGiacomo, V
Levin, B
Meruelo, D
description Genetic instability of cancer cells generates resistance after initial responses to chemotherapeutic agents. Several oncolytic viruses have been designed to exploit specific signatures of cancer cells, such as important surface markers or pivotal signaling pathways for selective replication. It is less likely for cancer cells to develop resistance given that mutations in these cancer signatures would negatively impact tumor growth and survival. However, as oncolytic viral vectors are large particles, they suffer from inefficient extravasation from tumor blood vessels. Their ability to reach cancer cells is an important consideration in achieving specific oncolytic targeting and potential vector replication. Our previous studies indicated that the Sindbis viral vectors target tumor cells by the laminin receptor. Here, we present evidence that modulating tumor vascular leakiness, using VEGF and/or metronomic chemotherapy regimens, significantly enhances tumor vascular permeability and directly enhances oncolytic Sindbis vector targeting in tumor models. Because host-derived vascular endothelium cells are genetically stable and less likely to develop resistance to chemotherapeutics, a combined metronomic chemotherapeutics and oncolytic vector regimen should provide a new approach for cancer therapy. This mechanism could explain the synergistic treatment outcomes observed in clinical trials of combined therapies.
doi_str_mv 10.1038/cgt.2009.70
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2841696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A222252622</galeid><sourcerecordid>A222252622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c626t-674b072f2cebfc5e59bf2bffff93071d66e777be14e25f8940360ff0658561113</originalsourceid><addsrcrecordid>eNqFks9vFCEUxydGY2v15F2JJnrQXYGZgZmLSdPUH0kTD-qZMMxjlsrAFphN9r-XcTfdrqkRDhDe533fD15RPCd4SXDZfFBDWlKM2yXHD4pTUnG2qGuMHxanuKXtgrS4PCmexHiNcTby8nFxQlreNoSS02K6dCvpFPQorkEZbRTqwZoNhC2SrkdJhgGScQPyGnmnvN2mzHw3ru9MRBsTpEUbUMmHiLotGn0_WfnHYSOjyveALMhfxkGMyDiUptGHp8UjLW2EZ_vzrPj56fLHxZfF1bfPXy_OrxaKUZYWjFcd5lRTBZ1WNdRtp2mn82pLzEnPGHDOOyAV0Fo3bYVLhrXGrG5qRggpz4qPO9311I3QK3Ap5yvWwYwybIWXRhxbnFmJwW8EbSrCWpYF3u4Fgr-ZICYxmqjAWunAT1HwqsqZ0pr8nyxL0tAG00y-_ou89lNwuQ-CsopwnKE58qt_UoRXTVU25CA1SAvCOO1zFWoOLM5pXnXObQ64vIfKu4fRKO9Am_x-5PDmjsMKpE2r6O2UjHfxGHy3A1XwMQbQt60lWMzDKfJwink4BceZfnH3Nw7sfhoz8H4HxGxyA4RDzffrvdzhTqYpwK1eZmYkE78By-33_Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217484381</pqid></control><display><type>article</type><title>Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tseng, J-C ; Granot, T ; DiGiacomo, V ; Levin, B ; Meruelo, D</creator><creatorcontrib>Tseng, J-C ; Granot, T ; DiGiacomo, V ; Levin, B ; Meruelo, D</creatorcontrib><description>Genetic instability of cancer cells generates resistance after initial responses to chemotherapeutic agents. Several oncolytic viruses have been designed to exploit specific signatures of cancer cells, such as important surface markers or pivotal signaling pathways for selective replication. It is less likely for cancer cells to develop resistance given that mutations in these cancer signatures would negatively impact tumor growth and survival. However, as oncolytic viral vectors are large particles, they suffer from inefficient extravasation from tumor blood vessels. Their ability to reach cancer cells is an important consideration in achieving specific oncolytic targeting and potential vector replication. Our previous studies indicated that the Sindbis viral vectors target tumor cells by the laminin receptor. Here, we present evidence that modulating tumor vascular leakiness, using VEGF and/or metronomic chemotherapy regimens, significantly enhances tumor vascular permeability and directly enhances oncolytic Sindbis vector targeting in tumor models. Because host-derived vascular endothelium cells are genetically stable and less likely to develop resistance to chemotherapeutics, a combined metronomic chemotherapeutics and oncolytic vector regimen should provide a new approach for cancer therapy. This mechanism could explain the synergistic treatment outcomes observed in clinical trials of combined therapies.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/cgt.2009.70</identifier><identifier>PMID: 19798121</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Alphavirus Infections - pathology ; Alphavirus Infections - therapy ; Alphavirus Infections - virology ; Animals ; Antineoplastic Agents, Phytogenic - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Blood vessels ; Blotting, Western ; Cancer ; Cancer therapies ; Care and treatment ; Cell Membrane Permeability ; Cellular signal transduction ; Chemotherapy ; Clinical trials ; Combined Modality Therapy ; Cricetinae ; Drug Delivery Systems ; Endothelium ; Extravasation ; Female ; Gene Expression ; Gene Therapy ; Genetic Vectors ; Genomic instability ; Health aspects ; Humans ; Laminin ; Mice ; Mice, SCID ; Neovascularization ; Neovascularization, Pathologic - prevention &amp; control ; Neuroblastoma - blood supply ; Neuroblastoma - therapy ; Neuroblastoma - virology ; Oncolysis ; Oncolytic Virotherapy ; original-article ; Ovarian Neoplasms - blood supply ; Ovarian Neoplasms - therapy ; Ovarian Neoplasms - virology ; Paclitaxel - therapeutic use ; Permeability ; Physiological aspects ; Replication ; Sindbis Virus - physiology ; Surface markers ; Tumor cells ; Tumors ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - metabolism ; Vectors ; Vectors (Biology) ; Viral vaccines ; Xenograft Model Antitumor Assays</subject><ispartof>Cancer gene therapy, 2010-04, Vol.17 (4), p.244-255</ispartof><rights>Springer Nature America, Inc. 2009</rights><rights>COPYRIGHT 2010 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2010</rights><rights>Nature Publishing Group 2009.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c626t-674b072f2cebfc5e59bf2bffff93071d66e777be14e25f8940360ff0658561113</citedby><cites>FETCH-LOGICAL-c626t-674b072f2cebfc5e59bf2bffff93071d66e777be14e25f8940360ff0658561113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/cgt.2009.70$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/cgt.2009.70$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19798121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tseng, J-C</creatorcontrib><creatorcontrib>Granot, T</creatorcontrib><creatorcontrib>DiGiacomo, V</creatorcontrib><creatorcontrib>Levin, B</creatorcontrib><creatorcontrib>Meruelo, D</creatorcontrib><title>Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><addtitle>Cancer Gene Ther</addtitle><description>Genetic instability of cancer cells generates resistance after initial responses to chemotherapeutic agents. Several oncolytic viruses have been designed to exploit specific signatures of cancer cells, such as important surface markers or pivotal signaling pathways for selective replication. It is less likely for cancer cells to develop resistance given that mutations in these cancer signatures would negatively impact tumor growth and survival. However, as oncolytic viral vectors are large particles, they suffer from inefficient extravasation from tumor blood vessels. Their ability to reach cancer cells is an important consideration in achieving specific oncolytic targeting and potential vector replication. Our previous studies indicated that the Sindbis viral vectors target tumor cells by the laminin receptor. Here, we present evidence that modulating tumor vascular leakiness, using VEGF and/or metronomic chemotherapy regimens, significantly enhances tumor vascular permeability and directly enhances oncolytic Sindbis vector targeting in tumor models. Because host-derived vascular endothelium cells are genetically stable and less likely to develop resistance to chemotherapeutics, a combined metronomic chemotherapeutics and oncolytic vector regimen should provide a new approach for cancer therapy. This mechanism could explain the synergistic treatment outcomes observed in clinical trials of combined therapies.</description><subject>Alphavirus Infections - pathology</subject><subject>Alphavirus Infections - therapy</subject><subject>Alphavirus Infections - virology</subject><subject>Animals</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood vessels</subject><subject>Blotting, Western</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell Membrane Permeability</subject><subject>Cellular signal transduction</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Cricetinae</subject><subject>Drug Delivery Systems</subject><subject>Endothelium</subject><subject>Extravasation</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>Genetic Vectors</subject><subject>Genomic instability</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Laminin</subject><subject>Mice</subject><subject>Mice, SCID</subject><subject>Neovascularization</subject><subject>Neovascularization, Pathologic - prevention &amp; control</subject><subject>Neuroblastoma - blood supply</subject><subject>Neuroblastoma - therapy</subject><subject>Neuroblastoma - virology</subject><subject>Oncolysis</subject><subject>Oncolytic Virotherapy</subject><subject>original-article</subject><subject>Ovarian Neoplasms - blood supply</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Ovarian Neoplasms - virology</subject><subject>Paclitaxel - therapeutic use</subject><subject>Permeability</subject><subject>Physiological aspects</subject><subject>Replication</subject><subject>Sindbis Virus - physiology</subject><subject>Surface markers</subject><subject>Tumor cells</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Vectors</subject><subject>Vectors (Biology)</subject><subject>Viral vaccines</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFks9vFCEUxydGY2v15F2JJnrQXYGZgZmLSdPUH0kTD-qZMMxjlsrAFphN9r-XcTfdrqkRDhDe533fD15RPCd4SXDZfFBDWlKM2yXHD4pTUnG2qGuMHxanuKXtgrS4PCmexHiNcTby8nFxQlreNoSS02K6dCvpFPQorkEZbRTqwZoNhC2SrkdJhgGScQPyGnmnvN2mzHw3ru9MRBsTpEUbUMmHiLotGn0_WfnHYSOjyveALMhfxkGMyDiUptGHp8UjLW2EZ_vzrPj56fLHxZfF1bfPXy_OrxaKUZYWjFcd5lRTBZ1WNdRtp2mn82pLzEnPGHDOOyAV0Fo3bYVLhrXGrG5qRggpz4qPO9311I3QK3Ap5yvWwYwybIWXRhxbnFmJwW8EbSrCWpYF3u4Fgr-ZICYxmqjAWunAT1HwqsqZ0pr8nyxL0tAG00y-_ou89lNwuQ-CsopwnKE58qt_UoRXTVU25CA1SAvCOO1zFWoOLM5pXnXObQ64vIfKu4fRKO9Am_x-5PDmjsMKpE2r6O2UjHfxGHy3A1XwMQbQt60lWMzDKfJwink4BceZfnH3Nw7sfhoz8H4HxGxyA4RDzffrvdzhTqYpwK1eZmYkE78By-33_Q</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Tseng, J-C</creator><creator>Granot, T</creator><creator>DiGiacomo, V</creator><creator>Levin, B</creator><creator>Meruelo, D</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>7QO</scope><scope>5PM</scope></search><sort><creationdate>20100401</creationdate><title>Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor</title><author>Tseng, J-C ; Granot, T ; DiGiacomo, V ; Levin, B ; Meruelo, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c626t-674b072f2cebfc5e59bf2bffff93071d66e777be14e25f8940360ff0658561113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Alphavirus Infections - pathology</topic><topic>Alphavirus Infections - therapy</topic><topic>Alphavirus Infections - virology</topic><topic>Animals</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood vessels</topic><topic>Blotting, Western</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell Membrane Permeability</topic><topic>Cellular signal transduction</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Cricetinae</topic><topic>Drug Delivery Systems</topic><topic>Endothelium</topic><topic>Extravasation</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>Genetic Vectors</topic><topic>Genomic instability</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Laminin</topic><topic>Mice</topic><topic>Mice, SCID</topic><topic>Neovascularization</topic><topic>Neovascularization, Pathologic - prevention &amp; control</topic><topic>Neuroblastoma - blood supply</topic><topic>Neuroblastoma - therapy</topic><topic>Neuroblastoma - virology</topic><topic>Oncolysis</topic><topic>Oncolytic Virotherapy</topic><topic>original-article</topic><topic>Ovarian Neoplasms - blood supply</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Ovarian Neoplasms - virology</topic><topic>Paclitaxel - therapeutic use</topic><topic>Permeability</topic><topic>Physiological aspects</topic><topic>Replication</topic><topic>Sindbis Virus - physiology</topic><topic>Surface markers</topic><topic>Tumor cells</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Vectors</topic><topic>Vectors (Biology)</topic><topic>Viral vaccines</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tseng, J-C</creatorcontrib><creatorcontrib>Granot, T</creatorcontrib><creatorcontrib>DiGiacomo, V</creatorcontrib><creatorcontrib>Levin, B</creatorcontrib><creatorcontrib>Meruelo, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tseng, J-C</au><au>Granot, T</au><au>DiGiacomo, V</au><au>Levin, B</au><au>Meruelo, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor</atitle><jtitle>Cancer gene therapy</jtitle><stitle>Cancer Gene Ther</stitle><addtitle>Cancer Gene Ther</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>17</volume><issue>4</issue><spage>244</spage><epage>255</epage><pages>244-255</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>Genetic instability of cancer cells generates resistance after initial responses to chemotherapeutic agents. Several oncolytic viruses have been designed to exploit specific signatures of cancer cells, such as important surface markers or pivotal signaling pathways for selective replication. It is less likely for cancer cells to develop resistance given that mutations in these cancer signatures would negatively impact tumor growth and survival. However, as oncolytic viral vectors are large particles, they suffer from inefficient extravasation from tumor blood vessels. Their ability to reach cancer cells is an important consideration in achieving specific oncolytic targeting and potential vector replication. Our previous studies indicated that the Sindbis viral vectors target tumor cells by the laminin receptor. Here, we present evidence that modulating tumor vascular leakiness, using VEGF and/or metronomic chemotherapy regimens, significantly enhances tumor vascular permeability and directly enhances oncolytic Sindbis vector targeting in tumor models. Because host-derived vascular endothelium cells are genetically stable and less likely to develop resistance to chemotherapeutics, a combined metronomic chemotherapeutics and oncolytic vector regimen should provide a new approach for cancer therapy. This mechanism could explain the synergistic treatment outcomes observed in clinical trials of combined therapies.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>19798121</pmid><doi>10.1038/cgt.2009.70</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0929-1903
ispartof Cancer gene therapy, 2010-04, Vol.17 (4), p.244-255
issn 0929-1903
1476-5500
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2841696
source MEDLINE; SpringerNature Journals; EZB-FREE-00999 freely available EZB journals
subjects Alphavirus Infections - pathology
Alphavirus Infections - therapy
Alphavirus Infections - virology
Animals
Antineoplastic Agents, Phytogenic - therapeutic use
Biomedical and Life Sciences
Biomedicine
Blood vessels
Blotting, Western
Cancer
Cancer therapies
Care and treatment
Cell Membrane Permeability
Cellular signal transduction
Chemotherapy
Clinical trials
Combined Modality Therapy
Cricetinae
Drug Delivery Systems
Endothelium
Extravasation
Female
Gene Expression
Gene Therapy
Genetic Vectors
Genomic instability
Health aspects
Humans
Laminin
Mice
Mice, SCID
Neovascularization
Neovascularization, Pathologic - prevention & control
Neuroblastoma - blood supply
Neuroblastoma - therapy
Neuroblastoma - virology
Oncolysis
Oncolytic Virotherapy
original-article
Ovarian Neoplasms - blood supply
Ovarian Neoplasms - therapy
Ovarian Neoplasms - virology
Paclitaxel - therapeutic use
Permeability
Physiological aspects
Replication
Sindbis Virus - physiology
Surface markers
Tumor cells
Tumors
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - metabolism
Vectors
Vectors (Biology)
Viral vaccines
Xenograft Model Antitumor Assays
title Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A13%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20specific%20delivery%20and%20targeting%20of%20oncolytic%20Sindbis%20viral%20vectors%20by%20modulating%20vascular%20leakiness%20in%20tumor&rft.jtitle=Cancer%20gene%20therapy&rft.au=Tseng,%20J-C&rft.date=2010-04-01&rft.volume=17&rft.issue=4&rft.spage=244&rft.epage=255&rft.pages=244-255&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/cgt.2009.70&rft_dat=%3Cgale_pubme%3EA222252622%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217484381&rft_id=info:pmid/19798121&rft_galeid=A222252622&rfr_iscdi=true